Age: 43.0
Sex: F
Vaccine: COVID19, COVID19, UNK
Symptoms: Arthralgia, COVID-19, Epistaxis, Immunodeficiency, Nasal dryness
Clinical narrative: Bloody nose; DRY NOSE; SINUS CONGESTION; Achy joints; COVID-19; IMMUNE RESPONSE WAS LITTLE AFTER MODERNA COVID VACCINE; ACHE AFTER MODERNA COVID VACCINE; RETURNED PSORIASIS SYMPTOMS; Scratchy throat after Moderna COVID vaccine; Head cold; PNEUMONIA; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNODEFICIENCY (IMMUNE RESPONSE WAS LITTLE AFTER MODERNA COVID VACCINE), PNEUMONIA (PNEUMONIA) and PSORIASIS (RETURNED PSORIASIS SYMPTOMS) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) solution for injection for Psoriatic arthritis and Plaque psoriasis and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Psoriatic arthritis and Plaque psoriasis (MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS).   On 15-Mar-2019, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free, in a prefilled pen. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. In June 2021, the patient experienced NASOPHARYNGITIS (Head cold) and PNEUMONIA (PNEUMONIA) (seriousness criterion medically significant). In October 2021, the patient experienced IMMUNODEFICIENCY (IMMUNE RESPONSE WAS LITTLE AFTER MODERNA COVID VACCINE) (seriousness criterion medically significant), PAIN (ACHE AFTER MODERNA COVID VACCINE), PSORIASIS (RETURNED PSORIASIS SYMPTOMS) (seriousness criterion medically significant) and THROAT IRRITATION (Scratchy throat after Moderna COVID vaccine). In April 2022, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced EPISTAXIS (Bloody nose), NASAL DRYNESS (DRY NOSE), SINUS CONGESTION (SINUS CONGESTION) and ARTHRALGIA (Achy joints). At the time of the report, IMMUNODEFICIENCY (IMMUNE RESPONSE WAS LITTLE AFTER MODERNA COVID VACCINE), PAIN (ACHE AFTER MODERNA COVID VACCINE), PSORIASIS (RETURNED PSORIASIS SYMPTOMS) and THROAT IRRITATION (Scratchy throat after Moderna COVID vaccine) was resolving, NASOPHARYNGITIS (Head cold) and PNEUMONIA (PNEUMONIA) had not resolved, EPISTAXIS (Bloody nose), NASAL DRYNESS (DRY NOSE) and SINUS CONGESTION (SINUS CONGESTION) outcome was unknown and COVID-19 (COVID-19) and ARTHRALGIA (Achy joints) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial On unknown dates, the patient experienced  plaques after Pfizer covid vaccine and achy joints after Pfizer covid vaccine. On unknown dates, plaques after Pfizer covid vaccine and achy joints after Pfizer covid vaccine  had resolved. In 2022, the event of COVID had resolved.     Treatment information was not provided.  Company Comment: This spontaneous case concerns a 43-year-old female patient, with relevant medical history of psoriasis and psoriatic arthropathy, who experienced the unexpected non-serious AESI COVID-19, unexpected serious (medically significant) Immunodeficiency (reported as immune response was little after Moderna COVID vaccine), Pneumonia, and Psoriasis (reported as psoriasis flare-up) that occurred on an unspecified date after receiving the dose of mRNA-1273 vaccine on an unknown date. Clinical course and treatment details were not reported. The event COVID-19 was reported resolved. Patient had received Tozinameran on an unknown date (Interchange of vaccine products). The medical history of psoriasis and psoriatic arthropathy could be confounders for the event psoriasis. The benefit-risk relationship of mRNA-1273 is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2022: Live significant follow-up received included: New events added,casualty updated,co suspect information updated.; Sender's Comments: This spontaneous case concerns a 43-year-old female patient, with relevant medical history of psoriasis and psoriatic arthropathy, who experienced the unexpected non-serious AESI COVID-19, unexpected serious (medically significant) Immunodeficiency (reported as immune response was little after Moderna COVID vaccine), Pneumonia, and Psoriasis (reported as psoriasis flare-up) that occurred on an unspecified date after receiving the dose of mRNA-1273 vaccine on an unknown date. Clinical course and treatment details were not reported. The event COVID-19 was reported resolved. Patient had received Tozinameran on an unknown date (Interchange of vaccine products). The medical history of psoriasis and psoriatic arthropathy could be confounders for the event psoriasis. The benefit-risk relationship of mRNA-1273 is not affected by this report.